Detalles de la búsqueda
1.
How much does Disease Activity Score in 28 joints ESR and CRP calculations underestimate disease activity compared with the Simplified Disease Activity Index?
Ann Rheum Dis
; 74(6): 1132-7, 2015 Jun.
Artículo
en Inglés
| MEDLINE | ID: mdl-25143522
2.
Maintenance, reduction, or withdrawal of etanercept after treatment with etanercept and methotrexate in patients with moderate rheumatoid arthritis (PRESERVE): a randomised controlled trial.
Lancet
; 381(9870): 918-29, 2013 Mar 16.
Artículo
en Inglés
| MEDLINE | ID: mdl-23332236
3.
Short-term efficacy of etanercept plus methotrexate vs combinations of disease-modifying anti-rheumatic drugs with methotrexate in established rheumatoid arthritis.
Rheumatology (Oxford)
; 53(11): 1984-93, 2014 Nov.
Artículo
en Inglés
| MEDLINE | ID: mdl-24907147
4.
Open-label observation of addition of etanercept versus a conventional disease-modifying antirheumatic drug in subjects with active rheumatoid arthritis despite methotrexate therapy in the Latin American region.
J Clin Rheumatol
; 20(1): 25-33, 2014 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-24356474
5.
Female patients with ankylosing spondylitis: analysis of the impact of gender across treatment studies.
Ann Rheum Dis
; 72(7): 1221-4, 2013 Jul.
Artículo
en Inglés
| MEDLINE | ID: mdl-23264358
6.
Improved health outcomes with etanercept versus usual DMARD therapy in an Asian population with established rheumatoid arthritis.
BMC Musculoskelet Disord
; 14: 13, 2013 Jan 08.
Artículo
en Inglés
| MEDLINE | ID: mdl-23294908
7.
Comparison of physician and patient global assessments over time in patients with rheumatoid arthritis: a retrospective analysis from the RADIUS cohort.
J Clin Rheumatol
; 19(6): 317-23, 2013 Sep.
Artículo
en Inglés
| MEDLINE | ID: mdl-23965479
8.
Combination etanercept and methotrexate provides better disease control in very early (<=4 months) versus early rheumatoid arthritis (>4 months and <2 years): post hoc analyses from the COMET study.
Ann Rheum Dis
; 71(6): 989-92, 2012 Jun.
Artículo
en Inglés
| MEDLINE | ID: mdl-22402142
9.
Comparison of health-related quality of life in rheumatoid arthritis, psoriatic arthritis and psoriasis and effects of etanercept treatment.
Ann Rheum Dis
; 71(7): 1143-50, 2012 Jul.
Artículo
en Inglés
| MEDLINE | ID: mdl-22258482
10.
Sensitivity and discriminatory ability of the Ankylosing Spondylitis Disease Activity Score in patients treated with etanercept or sulphasalazine in the ASCEND trial.
Rheumatology (Oxford)
; 51(10): 1894-905, 2012 Oct.
Artículo
en Inglés
| MEDLINE | ID: mdl-22772319
11.
Clinical efficacy and safety of etanercept versus sulfasalazine in patients with ankylosing spondylitis: a randomized, double-blind trial.
Arthritis Rheum
; 63(6): 1543-51, 2011 Jun.
Artículo
en Inglés
| MEDLINE | ID: mdl-21630245
12.
Reduced risk of infections with the intravenous immunoglobulin, IgPro10, in patients at risk of secondary immunodeficiency-related infections.
Immunotherapy
; 14(15): 1245-1261, 2022 10.
Artículo
en Inglés
| MEDLINE | ID: mdl-35971794
13.
Two-year clinical and radiographic results with combination etanercept-methotrexate therapy versus monotherapy in early rheumatoid arthritis: a two-year, double-blind, randomized study.
Arthritis Rheum
; 62(3): 674-82, 2010 Mar.
Artículo
en Inglés
| MEDLINE | ID: mdl-20187135
14.
Comparison of methotrexate monotherapy with a combination of methotrexate and etanercept in active, early, moderate to severe rheumatoid arthritis (COMET): a randomised, double-blind, parallel treatment trial.
Lancet
; 372(9636): 375-82, 2008 Aug 02.
Artículo
en Inglés
| MEDLINE | ID: mdl-18635256
15.
Response to: 'Impact of gender on outcomes in ankylosing spondylitis' by Feldtkeller et al.
Ann Rheum Dis
; 73(1): e3, 2014 Jan.
Artículo
en Inglés
| MEDLINE | ID: mdl-24218404
16.
The role of C-reactive protein as a predictor of treatment response in patients with ankylosing spondylitis.
Semin Arthritis Rheum
; 48(6): 997-1004, 2019 06.
Artículo
en Inglés
| MEDLINE | ID: mdl-30473179
17.
Predictors of remission with etanercept-methotrexate induction therapy and loss of remission with etanercept maintenance, reduction, or withdrawal in moderately active rheumatoid arthritis: results of the PRESERVE trial.
Arthritis Res Ther
; 20(1): 8, 2018 01 16.
Artículo
en Inglés
| MEDLINE | ID: mdl-29338762
18.
Patient Preferences Associated with Therapies for Psoriatic Arthritis: A Conjoint Analysis.
Am Health Drug Benefits
; 11(8): 408-417, 2018 Nov.
Artículo
en Inglés
| MEDLINE | ID: mdl-30647828
19.
Clinical and demographic factors associated with change and maintenance of disease severity in a large registry of patients with rheumatoid arthritis.
Arthritis Res Ther
; 19(1): 81, 2017 04 27.
Artículo
en Inglés
| MEDLINE | ID: mdl-28449692
20.
Long-term extension study of tofacitinib in refractory dermatomyositis.
Arthritis Rheumatol
; 74(2): 371-372, 2022 02.
Artículo
en Inglés
| MEDLINE | ID: mdl-34369109